Health Winners & Losers: Symmetry Medical
Tuesday proved a mixed day for biotech and health-care stocks. The Amex and Nasdaq biotechnology indices edged down 0.5% and 0.3%, while the Amex pharmaceutical index rose 0.9% to 289.93.
In the health-care space, two diagnostics companies got a lift from new analyst coverage. AspenBio Pharma (APPY) climbed 62 cents, or 13.4%, to $5.25 after Lazard Capital initiated coverage with a buy rating. Monogram Biosciences (MGRM) climbed 3 cents, or 2.8%, to $1.09 after JMP Securities initiated coverage with a market outperform rating.
Cardium Therapeutics (CXM) rose on news shares of the San Diego-based medical technology company, which trade on the Amex, have been selected for inclusion in the Russell Microcap Index. The stock rose 17 cents, or 7.7%, to $2.37.
Medical implant company Symmetry Medical (SMA) climbed after reporting first-quarter net income of $4 million, or 11 cents a share, up from $1.6 million, or 5 cents a share, a year ago. Excluding charges, the company earned 20 cents a share on $101.9 million in revenue. Analysts were looking for EPS of 14 cents on revenue of $88.4 million, according to Thomson Reuters data. The stock rose $1.08, or 7.3%, to $15.96.On the losing side, Invitrogen (IVGN) slid despite an upgrade by JP Morgan from neutral to overweight. The stock fell 78 cents, or 2%, to $39.23. Goldman downgraded Charles River Laboratories (CRL) to neutral from buy based on valuation following the stock's recent strength. The stock is about 13% from Goldman's $13 price target of $73. The stock traded Tuesday as low as 3.5% down, but ended with a loss of just 61 cents, or 0.9%, at $64.27.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV